Trials / Completed
CompletedNCT02835365
Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France
Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in French Gastro and Hepatology Departments
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 218 (actual)
- Sponsor
- Centre Hospitalier Intercommunal Creteil · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in neurology to treat spastic contracture. Several clinical studies have suggested its efficacy in the treatment of alcohol-dependence in low, even in case of cirrhosis and high dose. French drug authority has authorized its use in 2012 whereas the l'European Association for the Study of the Liver recommends to perform additional studies on this indication. The goal of this observational study is to evaluate the use of baclofen for alcohol-dependence in real life care as well its efficacy.
Detailed description
Numerous centers of the French research group of the national association of the hepatologists and gastroenterologists from general hospitals (ANGH) will be part of this study. Patients treated with baclofen for alcohol -dependence will be enroll prospectively from 2014 and retrospectively if they were treated between 2012 and 2014. The reported alcohol consumption, biological markers of excessive alcohol, initial and usual baclofen dosage, blood balofen dosage as well as clinical data will be collected.
Conditions
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-08-01
- Completion
- 2018-09-01
- First posted
- 2016-07-18
- Last updated
- 2023-01-12
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02835365. Inclusion in this directory is not an endorsement.